Who we are
Open Biosystems was founded in 2001 by a
team of researchers who believe deeply in the power of science to
improve our lives, and yours, too. This conviction, coupled with our
strong desire to help our customers succeed, motivates our employees
and gives us our unrelenting focus on developing and delivering the
best life sciences tools, support and services to our customers
available in the industry today.
Our business model, based on a collaborative spirit and focused on the
value of product delivery, is inspired by the success of the open
source movement in software. Open source has, over the span of just a
few years, radically empowered small organizations and individuals by
giving them the tools only big companies could previously afford. We
aim to speed the progress of research by letting people use our
technology in a manner that’s substantially more flexible than that of
other tools providers.
Open Biosystems offers products that span Genomics, RNAi and
Antibodies. Building on the rapid sharing model that is at the core of
the Human Genome Project, Open Biosystems collaborates with some of the
most innovative life science investigators working today. We partner
with them to bring to market new products—they have often pioneered the
new resources in their own lab, and we prepare it for widespread use
and then provide access to the research community.
Delivery of genetic content is our most recent technological
breakthrough. Recently, we brought to market the Tranz-vector system,
the safest human-based lentiviral delivery technology. Further
supplementing our already strong line of RNA interference (RNAi) and
complementary DNA (cDNA) products, this technology provides
investigators with superior delivery capabilities for high-quality
cellular screening. The combination or our unique Tranz-vector system
and whole genome RNAi & cDNA content enables our customers to
perform drug target validation on a large scale.
With our genomics resources, Open Biosystems provides the content
investigators utilize to unlock the functions of human genes and their
relationships to normal & disease development. We offer the most
complete gene library in the industry. This novel library consists of
several full length cDNA and open reading frame collections. Most
prominently among these is the Mammalian Gene Collection (MGC), the
industry’s gold standard gene catalog.
The discovery of RNA interference has revolutionized the way
investigators approach the studies of gene expression, regulation and
interactions, particularly as it relates to drug development. Our
collaboration with Drs. Greg Hannon (CSHL) and Steve Elledge (Harvard)
has led the way in the evolution of the short hairpin RNA (shRNA)
technologies to provide the life science community with whole genome
resources for human, mouse and rat with a multitude of technology and
delivery advantages.
